Compare Invesco NASDAQ 100 ETF (QQQM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $294.62, while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals.
| QQQM | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $852.03 |
52-Week Low | $229.87 | $555.51 |
Market Cap | — | $83.43B |
Enterprise Value | — | $78.14B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $295.76, down 0.1% with a bullish technical signal from moving averages. The ETF tracks the Nasdaq-100 index, offering diversified exposure to large-cap growth stocks. Recent news highlights QQQM's low expense ratio advantage over QQQ and its position as a core growth allocation option for investors seeking Nasdaq-100 exposure.
The outlook remains positive for long-term growth investors, with technical indicators supporting bullish momentum. Key risks include concentration in top holdings and market sensitivity to technology sector performance. The ETF's low-cost structure provides a competitive advantage for sustained investment.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
